NCI-N87

NCI-N87 (Gastric Cancer CDX Model) 

The NCI-N87 gastric cancer line was derived from a human gastric adenocarcinoma. It is HER2-amplified, making it highly relevant for HER2-targeted therapy research. NCI-N87 has been extensively used in biomarker and drug screening studies. Its reproducibility makes it valuable in gastric cancer pipelines. 

Key Features: 

• Derived from gastric adenocarcinoma. 

• HER2-amplified gastric cancer model. 

• Epithelial morphology. 

• Tumorigenic in xenografts. 

Applications: 
NCI-N87 is used in HER2-targeted drug discovery for gastric cancer. Researchers apply it to biomarker validation and combination therapy testing. It supports resistance mechanism research in HER2-positive disease. Its stable biology makes it widely adopted in translational studies.